Yun Zhong
Stock Analyst at Wedbush
(0.68)
# 3,707
Out of 4,711 analysts
26
Total ratings
34.78%
Success rate
-14.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PASG Passage Bio | Assumes: Outperform | $4 | $0.66 | +506.06% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $52.17 | +39.93% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $4.39 | +173.35% | 1 | Nov 5, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $58 | $41.49 | +39.79% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.63 | +224.45% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $1.85 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $9.80 | +63.27% | 1 | Jan 18, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $160 | $118.97 | +34.49% | 11 | Dec 22, 2022 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $35 | $11.56 | +202.77% | 1 | Nov 1, 2022 | |
| BLUE bluebird bio | Downgrades: Hold | $700 | $8.50 | +8,135.29% | 2 | Jul 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $16.98 | +170.91% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.35 | +198.51% | 1 | May 5, 2021 |
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.66
Upside: +506.06%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $52.17
Upside: +39.93%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $4.39
Upside: +173.35%
Protagonist Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $58
Current: $41.49
Upside: +39.79%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.63
Upside: +224.45%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.85
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $9.80
Upside: +63.27%
Sarepta Therapeutics
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $118.97
Upside: +34.49%
Rocket Pharmaceuticals
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $11.56
Upside: +202.77%
bluebird bio
Jul 1, 2021
Downgrades: Hold
Price Target: $700
Current: $8.50
Upside: +8,135.29%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $16.98
Upside: +170.91%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $3.35
Upside: +198.51%